BioMed Research International / 2017 / Article / Tab 2 / Review Article
Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications Table 2 Applications of ctDNA quantification and monitoring for melanoma patients. PBL: peripheral blood lymphocytes.
Gene Sample Application References BRAF Serum (i) Tumor response monitoring (ii) Prognostic value [17 ] BRAF Serum/plasma Advanced stage IV monitoring [9 ] BRAF Serum Identification of genetic determinants for targeted therapy [3 ] BRAF Plasma Identification of genetic determinants for targeted therapy [21 ] BRAF Serum/plasma Identification of genetic determinants for targeted therapy [19 ] BRAF Plasma Identification of genetic determinants for targeted therapy [36 ] BRAF PBL (i) Identification of genetic determinants for targeted therapy (ii) Evaluation of early treatment response (iii) Monitoring of minimal residual disease [22 ] GNAQ GNA11 Plasma Prognostic value [26 ] BRAF Plasma (i) Identification of genetic determinants for targeted therapy (ii) Monitoring of tumor dynamics (iii) Prognostic value [28 ] BRAF NRAS TERT PromoterPlasma Evaluation of early treatment response to immunotherapy [33 ] BRAF Plasma/serum (i) Prognostic value (ii) Monitoring of tumor dynamics (iii) Evaluation of early treatment response (iv) Monitoring of minimal residual disease [18 ] BRAF Plasma Prognostic value [32 ] BRAF NRAS Plasma (i) Monitoring of tumor dynamics (ii) Monitoring of minimal residual disease (iii) Real-time assessment of resistance [30 ] BRAF Plasma Prognostic value [34 ] BRAF Plasma (i) Prognostic value (ii) Monitoring of tumor dynamics (iii) Evaluation of early treatment response (iv) Real-time assessment of resistance [34 ] BRAF NRAS Plasma (i) Prognostic value (ii) Evaluation of early treatment response (iii) Real-time assessment of resistance [30 ] BRAF Plasma (i) Identification of genetic determinants for targeted therapy (ii) Prognostic value [20 ] Exome Plasma (i) Evaluation of early treatment response (ii) Real-time assessment of resistance [35 ]